Immutep Quarterly Activities Report and Appendix 4C
Filed with ASX · · 12 pages · English
Summary by 6ix AI
The report highlights a strategic collaboration with Dr. Reddy’s for the commercialization of efti, including an upfront payment and potential milestone payments. Immutep reported strong progress in ongoing clinical trials for efti in various cancers, including non-small cell lung cancer and soft tissue sarcoma.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Story so far
Earlier from Immutep
- Immutep Announces Positive Update on IMP761, a First-in-Class LAG-3 Agonist Antibody for Autoimmune Diseases, from Phase I Study
- Positive Update on IMP761 Phase 1
- Immutep Announces Strong Operational Progress in Global TACTI-004 (KEYNOTE-F91) Phase III and Enrolment Continues at Robust Pace
- TACTI-004 phase III trial enrolment continues at robust pace
- Immutep and Dr. Reddy’s enters into Strategic Collaboration for Commercialisation of an Innovative Oncology Drug, Eftilagimod Alfa
Later from Immutep
- Immutep Quarterly Activities Report Q2 FY26
- Immutep Achieves 50% Enrolment in Global TACTI-004-1L NSCLC
- Immutep Achieves 50% Enrolment in Global TACTI-004 (KEYNOTE-F91) Phase III Trial in 1L NSCLC
- Half Yearly Report and Accounts
- Trading Halt
Follow Immutep into a list and get an email when it puts out news.
Follow Immutep